Make 10 slides from the article "Time to Next Treatment Within 24 Months (TTNT24) as a Predictor of Survival in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: A Population-Based Observational Study" with Introduction, Methods, Results, Discussion and Conclusion with Perspectivation
Make 10 slides from the article "Time to Next Treatment Within 24 Months (TTNT24) as a Predictor of Survival in Lymphoplasmacytic Lymphoma/Waldenström Macroglobulinemia: A Population-Based Observational Study" with Introduction, Methods, Results, Discussion and Conclusion with Perspectivation
Created using ChatSlide
The TTNT24 study investigates the dynamic aggressiveness of disease in a cohort of 526 patients with LPL/WM from 2000 to 2023. Results indicate that TTNT24 positivity correlates with a median overall survival of 61 months and significant prognostic separation. The study highlights the importance of dynamic markers in enhancing existing models while acknowledging potential biases. Future validation in targeted-therapy cohorts is recommended to strengthen findings.